TRACON Pharmaceuticals Inc (TCON.OQ)
14 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
- BRIEF-Tracon Pharmaceuticals announces positive results from phase 1 trial of TRC102, Fludara
- BRIEF-Tracon Pharma reports third quarter financial results
- BRIEF-683 Capital Management reports 5.4 pct passive stake in Tracon Pharmaceuticals
- BRIEF-Tracon Pharmaceuticals announces completion of enrollment in randomized phase 2B traxar study of TRC105 and Inlyta in renal cell carcinoma
- BRIEF-Tracon Pharmaceuticals files for offering of up to $14.33 mln of co's common stock